Adding the proteasome inhibitor Velcade (bortezomib) to the standard therapy of Revlimid (lenalidomide) and dexamethasone — a triple combo therapy — significantly extends progression-free survival and…
News
Researchers have discovered a mechanism underlying the development of treatment resistance to proteasome inhibitors in multiple myeloma. Surprisingly, the mechanism also was linked to a…
Cancer Treatment Centers of America (CTCA) recently began enrolling patients with cancer for the clinical trial study TAPUR — Targeted Agent and Profiling Utilization Registry.
Early treatment with a combination of anti-cancer drugs in patients with smoldering myeloma, who are at high risk of developing multiple myeloma, may avoid disease…
The monoclonal antibody Darxalex (daratumumab) was recently approved by the U.S. Food and Drug Administration (FDA), in combination with either Revlimid (lenalidomide) and dexamethasone, or…
Aduro Biotech recently presented positive preclinical data showing that its monoclonal antibody, BION-1301, may successfully inhibit multiple myeloma tumor growth, survival, and resistance to other…
The results of a new clinical trial suggest that two extension treatments that are frequently added to standard therapy care in patients with multiple…
Patients with advanced multiple myeloma may benefit from bluebird bio’s novel CAR T-cell therapy bb2121, according to data presented at the 28th EORTC-NCI-AACR Molecular…
A technique called extracorporeal blood purification (EBP) could be used to remove certain molecules from the blood and potentially treat different conditions including multiple myeloma and kidney complications associated with it.
Patients in a precancerous stage of multiple myeloma would be wise to avoid gaining extra weight, according to new research that shows being overweight or obese…
